Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
4 března, 2021 5:51 pmAuthor(s): Jesus San-Miguel, Katja Weisel, Gordon Cook, et al. Abstract: S 101 Session topic: 14. Myeloma and other...
MNOHOPOČETNÝ MYELÓM
4 března, 2021 5:49 pmNa kongrese EHA 2017 bol mnohopočetnému myelómu (MM) venovaný značný priestor v rámci edukačného a satelitných sympózií, vedeckej pracovnej skupiny a taktiež v posterovej sekcii....
QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
4 března, 2021 5:37 pmAuthor(s): Nigel Russell, Martin S. Tallman, Stuart Goldberg Abstract: ABSSUB-4757 Session topic: 4. Acute myeloid leukemia – Clinical...
ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO REQUIRE TWO COURSES OF INDUCTION THERAPY TO ACHIEVE COMPLETE REMISSION (CR) SHOULD UNDERGO ALLOGENEIC TRANSPLANT (ALLO-SCT) DURING THE FIRST CR
4 března, 2021 5:32 pmAuthor(s): Hiroaki Shimizu, Hiroshi Handa, Nahoko Hatsumi, et al. Abstract: ABSSUB-4989 Session topic: 4. Acute myeloid leukemia –...
RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
4 března, 2021 5:29 pmAuthor(s): Hervé Dombret, John F. Seymour, Aleksandra Butrym, et al. Abstract: LB-6212 Session topic: 4. Acute myeloid leukemia...
VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION
4 března, 2021 5:26 pmAuthor(s): Jae-Ho Yoon, Hee-Je Kim, Young-Woo Jeon, et al. Abstract: ABSSUB-3999 Session topic: 4. Acute myeloid leukemia –...
AKUTNÍ MYELOIDNÍ LEUKEMIE – NOVINKY Z KONFERENCE EVROPSKÉ HEMATOLOGICKÉ SPOLEČNOSTI
4 března, 2021 5:08 pmKonference EHA se věnovala extenzivně oblasti preleukemických predispozičních stavů a dále vlivu stárnutí na vznik a léčebné možnosti akutní myeloidní leukemie (AML). V oblastech...
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
4 března, 2021 4:58 pmAuthor(s): James Bussel, Michael Tarantino, Victor Blanchette, et al. Abstract: P727 Session topic: 32. Platelets disorders Background:...
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
4 března, 2021 4:48 pmAuthor(s): J Bussel, J Mayer, L Cervinek, K Chojnowski, et al. Abstract: S435 Session topic: 32. Platelets disorders...
REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY
4 března, 2021 4:45 pmAuthor(s): Emilio Ojeda Gutiérrez, Abdulgabar Salama, Jean-François Viallard, et al. Abstract: P 720 Session topic: 32. Platelets disorders...